Guy Goodwin
FMedSci
Emeritus Professor of Psychiatry
The development of better ways to treat mood disorders
My research interests are in the treatment of bipolar disorder and the application of neuroscience and technology in understanding the neurobiology of mood disorders, with a focus on developing new treatments.
I was formerly W.A.Handley Chair of Psychiatry and head of the University department of Psychiatry (1996-2011).
I am a Fellow of the American College of Neuropsychopharmacology, and have previously held the positions of President of the British Association for Psychopharmacology (2004–2005) and of the European College of Neuropsychopharmacology (ECNP, 2013-2016).
I am an Emeritus Senior Investigator on the faculty of UK National Institute for Health Research (NIHR).
I am a Thomson Reuters highly cited researcher (top 1% in field).
Recent publications
-
A single dose of lamotrigine induces a positive memory bias in healthy volunteers.
Journal article
Zghoul T. et al, (2025), Psychol Med, 55
-
Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder.
Journal article
Goodwin GM. et al, (2025), J Clin Psychiatry, 86
-
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.
Journal article
Goodwin GM. et al, (2025), J Affect Disord, 372, 523 - 532
-
Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions.
Journal article
Kirlić N. et al, (2025), Am J Psychiatry, 182, 126 - 132
-
The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression.
Journal article
Marwood L. et al, (2024), J Psychiatr Res, 180, 198 - 203